Stockscreener 앱 받기
4.96
0.20%
-0.010
시간 외 거래:
4.92
-0.04
-0.81%
전일 마감가:
$4.97
열려 있는:
$4.92
하루 거래량:
5.89M
Relative Volume:
1.61
시가총액:
$1.17B
수익:
$251.85M
순이익/손실:
$-72.58M
주가수익비율:
-41.33
EPS:
-0.12
순현금흐름:
$-63.80M
1주 성능:
+1.33%
1개월 성능:
-15.07%
6개월 성능:
-36.49%
1년 성능:
+14.55%
1일 변동 폭
$4.714
$5.06
1주일 범위
$4.43
$5.06
52주 변동 폭
$4.06
$10.13
Ardelyx Inc Stock (ARDX) Company Profile
명칭
Ardelyx Inc
전화
510-745-7047
주소
34175 ARDENWOOD BLVD., FREMONT, CA
ARDX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
| ARDX | 4.96 | 1.17B | 251.85M | -72.58M | -63.80M | -0.12 |
| VRTX | 467.01 | 119.87B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 762.00 | 83.27B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 567.90 | 33.96B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 232.27 | 30.18B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 101.87 | 24.42B | 3.30B | -501.07M | 1.03B | 11.54 |
Ardelyx Inc Stock (ARDX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-07-02 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-04-05 | 개시 | Leerink Partners | Outperform |
| 2023-12-18 | 개시 | Raymond James | Strong Buy |
| 2023-09-07 | 개시 | H.C. Wainwright | Buy |
| 2023-08-25 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2023-03-03 | 업그레이드 | Wedbush | Neutral → Outperform |
| 2022-11-17 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2022-05-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2021-12-01 | 업그레이드 | Ladenburg Thalmann | Neutral → Buy |
| 2021-10-14 | 다운그레이드 | Ladenburg Thalmann | Buy → Neutral |
| 2021-07-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2021-07-20 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-07-20 | 다운그레이드 | Wedbush | Outperform → Neutral |
| 2021-03-23 | 개시 | Wedbush | Outperform |
| 2021-01-06 | 개시 | Cantor Fitzgerald | Overweight |
| 2020-10-20 | 재개 | Citigroup | Buy |
| 2020-02-18 | 재개 | Jefferies | Buy |
| 2020-02-12 | 개시 | Citigroup | Buy |
| 2020-02-10 | 개시 | Cowen | Outperform |
| 2019-04-08 | 개시 | Piper Jaffray | Overweight |
| 2018-08-24 | 개시 | Jefferies | Buy |
| 2018-03-19 | 재개 | Leerink Partners | Outperform |
| 2017-11-29 | 재확인 | Citigroup | Buy |
| 2017-11-22 | 재확인 | Ladenburg Thalmann | Buy |
| 2017-10-17 | 재개 | Leerink Partners | Outperform |
| 2016-03-31 | 개시 | Ladenburg Thalmann | Buy |
| 2016-03-09 | 개시 | Cantor Fitzgerald | Buy |
| 2016-03-03 | 개시 | Citigroup | Buy |
모두보기
Ardelyx Inc 주식(ARDX)의 최신 뉴스
US Penny Stocks To Monitor In November 2024 - Simply Wall St
Ardelyx, Inc. (NASDAQ:ARDX) Sees Large Increase in Short Interest - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Ardelyx (NASDAQ:ARDX) Shares Gap UpTime to Buy? - MarketBeat
Janus Henderson Group PLC's Strategic Reduction in Ardelyx Inc H - GuruFocus.com
Director David Mott Acquires 215,868 Shares of Ardelyx Inc (ARDX) - GuruFocus.com
Ardelyx's Medicare Setback Casts Doubt On Long-Term Viability (NASDAQ:ARDX) - Seeking Alpha
HC Wainwright Has Bearish Forecast for Ardelyx Q1 Earnings - MarketBeat
Ardelyx shares downgraded amid sales concerns for XPHOZAH By Investing.com - Investing.com Australia
Ardelyx down as H.C. Wainwright downgrades rating on anticipated Xphozah sales drop - Seeking Alpha
Ardelyx (NASDAQ:ARDX) Sees Unusually-High Trading VolumeWhat's Next? - MarketBeat
Ardelyx shares downgraded amid sales concerns for XPHOZAH - Investing.com India
Ardelyx (NASDAQ:ARDX) Lowered to Neutral Rating by HC Wainwright - MarketBeat
Ardelyx chief development officer sells shares worth $165,743 - Investing.com India
Ardelyx chief development officer sells shares worth $165,743 By Investing.com - Investing.com Australia
David P. Rosenbaum Sells 27,171 Shares of Ardelyx, Inc. (NASDAQ:ARDX) Stock - MarketBeat
Ardelyx Beats Q3 Sales Estimates, Shares Climb - MSN
Ardelyx Loses Bid to Block HHS Classification of Kidney Drug - Bloomberg Law
Ardelyx tumbles as lawsuit against CMS dismissed over Xphozah (update) - MSN
Ardelyx Responds to District Court Decision Granting Motion to Dismiss - The Manila Times
Ardelyx (NASDAQ:ARDX) Shares Gap DownTime to Sell? - MarketBeat
Ardelyx ‘disappointed’ by court decision granting motion to dismiss - TipRanks
Ardelyx Stock Alert: Court Dismisses CMS Lawsuit, XPHOZAH Access Concerns Mount | ARDX Stock News - StockTitan
Ardelyx falls after court dismisses lawsuit against CMS over company's kidney disease drug - XM
Ardelyx chief development officer sells $161,673 in stock - Investing.com
Ardelyx chief development officer sells $161,673 in stock By Investing.com - Investing.com Canada
(ARDX) Investment Analysis - Stock Traders Daily
Citigroup Lowers Ardelyx (NASDAQ:ARDX) Price Target to $10.00 - Defense World
Ardelyx to Participate at the 2024 Jefferies London Healthcare Conference - ForexTV.com
Ardelyx (ARDX) Leadership to Present at Jefferies London Healthcare Conference 2024 | ARDX Stock News - StockTitan
What is Wedbush’s Forecast for Ardelyx FY2026 Earnings? - Defense World
ARDX Investors Have Opportunity to Lead Ardelyx, Inc.Securities Fraud Lawsuit with the Schall Law Firm - GuruFocus.com
ARDX LAWSUIT ALERT: Levi & Korsinsky Notifies Ardelyx, Inc. Inve - GuruFocus.com
Ardelyx (NASDAQ:ARDX) Price Target Lowered to $10.00 at Citigroup - MarketBeat
Wedbush Has Negative Outlook for Ardelyx FY2026 Earnings - MarketBeat
Ardelyx, Inc. (NASDAQ:ARDX) Q3 2024 Earnings Call Transcript - MSN
Earnings Update: Ardelyx, Inc. (NASDAQ:ARDX) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts - Simply Wall St
Ardelyx (NASDAQ:ARDX) Stock Price Up 7.3% – Here’s Why - Defense World
Allspring Global Investments Holdings LLC Sells 19,212 Shares of Ardelyx, Inc. (NASDAQ:ARDX) - Defense World
Lost Money on Ardelyx, Inc.(ARDX)? Join Class Action Suit Seekin - GuruFocus.com
Ardelyx Third Quarter 2024 Earnings: US$0.003 loss per share (vs US$0.03 profit in 3Q 2023) - Yahoo Finance
Compared to Estimates, Ardelyx (ARDX) Q3 Earnings: A Look at Key Metrics - MSN
Ardelyx (NASDAQ:ARDX) Earns "Buy" Rating from HC Wainwright - MarketBeat
Earnings call: Ardelyx reports solid growth amid Medicare challenges - Investing.com
Earnings call: Ardelyx reports solid growth amid Medicare challenges By Investing.com - Investing.com Canada
Ardelyx (NASDAQ:ARDX) Shares Up 7.3%Should You Buy? - MarketBeat
Ardelyx Target of Unusually High Options Trading (NASDAQ:ARDX) - MarketBeat
Ardelyx Surpasses Q3 Revenue Estimates - The Motley Fool
Ardelyx CEO Michael Raab sells $147,740 in stock By Investing.com - Investing.com Australia
Ardelyx Inc (ARDX) Q3 2024 Earnings Call Highlights: Revenue Surge and Strategic Growth Amidst ... - Yahoo Finance
Ardelyx CEO Michael Raab sells $147,740 in company stock By Investing.com - Investing.com Canada
Ardelyx Inc (ARDX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.66%
1.11%
자본화:
|
볼륨(24시간):